Cumberland Pharmaceuticals Receives FDA Approval for RediTrex™ Product Line
Last cumberland pharmaceuticals, inc earnings: 11/12 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations: investor.shareholder.com/cpix/index.cfm

Impact snapshot | Event time: | CPIX | ||||
---|---|---|---|---|---|---|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last price | ||
VWAP | ||
High:
|
Max up |
High:
|
Low:
|
Max down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event Day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance Since Event
Time and Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
SIGN UP TODAY
Opt-in for
CPIX alerts
CPIX alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CPIX alerts
High impacting Cumberland Pharmaceuticals, Inc news events
Weekly update
A roundup of the hottest topics
CPIX
News
- Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX) had its price target raised by analysts at B. Riley from $9.00 to $9.75. They now have a "buy" rating on the stock.MarketBeat
- New Study Reveals Real-World Usage of Vibativ® In a Variety Of InfectionsPR Newswire
- Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating.MarketBeat
- Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX) had its price target lowered by analysts at B. Riley from $12.25 to $9.00. They now have a "buy" rating on the stock.MarketBeat
- Cumberland Pharmaceuticals' (CPIX) CEO A. J. Kazimi on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- More
CPIX
SEC Filings
- 12/6/19 - Form 8-K
- 12/6/19 - Form 4
- 11/29/19 - Form 4
- CPIX's page on the SEC website
- More